Transforming LGMD through Pioneering Gene Therapies


Our Vision

To transform the lives of people with LGMD and their families by delivering the first-ever corrective gene therapies for this community.

Positively Transforming Lives

Myonexus Therapeutics is advancing a promising pipeline of first-ever gene therapy treatments for Limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C.

Our Progress

Myonexus Therapeutics in the News

Myonexus Therapeutics Announces Accelerated Acquisition by Sarepta Therapeutics 150 150 Myonexus Therapeutics

Myonexus Therapeutics Announces Accelerated Acquisition by Sarepta Therapeutics

Companies to Exercise Purchase Option Agreement Following Positive, Preliminary Data in Limb-Girdle Muscular Dystrophy Type 2E Program NEW ALBANY, Ohio, February 27, 2019 — Myonexus…

read more
Myonexus Therapeutics Receives Orphan Drug Designation for MYO-102, an Investigational Gene Therapy for Alpha-sarcoglycanopathy (LGMD2D) 150 150 Myonexus Therapeutics

Myonexus Therapeutics Receives Orphan Drug Designation for MYO-102, an Investigational Gene Therapy for Alpha-sarcoglycanopathy (LGMD2D)

NEW ALBANY, Ohio, January 2, 2019 — Myonexus Therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation…

read more
Myonexus Therapeutics Announces the Initiation of a Trial for the First-Ever Gene Therapy for Betasarcoglycanopathy, Also Known as Limb-Girdle Muscular Dystrophy Type 2E 150 150 Myonexus Therapeutics

Myonexus Therapeutics Announces the Initiation of a Trial for the First-Ever Gene Therapy for Betasarcoglycanopathy, Also Known as Limb-Girdle Muscular Dystrophy Type 2E

First-in-human trial of MYO-101 based on promising pre-clinical results offering the first corrective approach for LGMD2E NEW ALBANY, Ohio, November 8, 2018 — Myonexus Therapeutics,…

read more